<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39426837</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>404</Volume><Issue>10462</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.</ArticleTitle><Pagination><StartPage>1547</StartPage><EndPage>1559</EndPage><MedlinePgn>1547-1559</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(24)01738-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(24)01738-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Respiratory syncytial virus vaccines first recommended for use during 2023 were efficacious against lower respiratory tract disease in clinical trials. Limited real-world data regarding respiratory syncytial virus vaccine effectiveness are available. To inform vaccine policy and address gaps in evidence from the clinical trials, we aimed to assess the effectiveness against respiratory syncytial virus-associated hospitalisations and emergency department encounters among adults aged at least 60 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a test-negative design analysis in an electronic health records-based network in eight states in the USA, including hospitalisations and emergency department encounters with respiratory syncytial virus-like illness among adults aged at least 60 years who underwent respiratory syncytial virus testing from Oct 1, 2023, to March 31, 2024. Respiratory syncytial virus vaccination status at the time of the encounter was derived from electronic health record documentation, state and city immunisation registries, and, for some sites, medical claims. Vaccine effectiveness was estimated by immunocompromise status, comparing the odds of vaccination among respiratory syncytial virus-positive case patients and respiratory syncytial virus-negative control patients, and adjusting for age, race and ethnicity, sex, calendar day, social vulnerability index, number of underlying non-respiratory medical conditions, presence of respiratory underlying medical conditions, and geographical region.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Among 28&#x2008;271 hospitalisations for respiratory syncytial virus-like illness among adults aged at least 60 years without immunocompromising conditions, vaccine effectiveness was 80% (95% CI 71-85) against respiratory syncytial virus-associated hospitalisations, and vaccine effectiveness was 81% (52-92) against respiratory syncytial virus-associated critical illness (ICU admission or death, or both). Among 8435 hospitalisations for respiratory syncytial virus-like illness among adults with immunocompromising conditions, vaccine effectiveness was 73% (48-85) against associated hospitalisation. Among 36&#x2008;521 emergency department encounters for respiratory syncytial virus-like illness among adults aged at least 60 years without an immunocompromising condition, vaccine effectiveness was 77% (70-83) against respiratory syncytial virus-associated emergency department encounters. Vaccine effectiveness estimates were similar by age group and product type.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Respiratory syncytial virus vaccination was effective in preventing respiratory syncytial virus-associated hospitalisations and emergency department encounters among adults aged at least 60 years in the USA during the 2023-24 respiratory syncytial virus season, which was the first season after respiratory syncytial virus vaccine was approved.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">The Centers for Disease Control and Prevention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Published by Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Payne</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: bvx2@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Janet A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Patrick K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dascomb</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Center for Health Research, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Nicola P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grannis</LastName><ForeName>Shaun J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine, Indianapolis, IN, USA; Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Sarah W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeSilva</LastName><ForeName>Malini B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>HealthPartners Institute, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheffield</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bride</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arndorfer</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naleway</LastName><ForeName>Allison L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Center for Health Research, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koppolu</LastName><ForeName>Padma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Center for Health Research, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fireman</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerbo</LastName><ForeName>Ousseny</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timbol</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goddard</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dixon</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Health Policy and Management, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadel</LastName><ForeName>William F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Biostatistics and Health Data Science, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogerson</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Katie S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Health Policy and Management, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Suchitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barron</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reese</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowley</LastName><ForeName>Elizabeth A K</ForeName><Initials>EAK</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najdowski</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Eagle Health Analytics, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciesla</LastName><ForeName>Allison Avrich</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Eagle Health Analytics, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Emily L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akinsete</LastName><ForeName>Omobosola O</ForeName><Initials>OO</Initials><AffiliationInfo><Affiliation>HealthPartners Institute, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Charlene E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>HealthPartners Institute, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Essien</LastName><ForeName>Inih J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>HealthPartners Institute, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenforde</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming-Dutra</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Link-Gelles</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; United States Public Health Service Commissioned Corps, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022261">Respiratory Syncytial Virus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="Y">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022261" MajorTopicYN="Y">Respiratory Syncytial Virus Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="Y">Emergency Service, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="Y">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="N">Respiratory Syncytial Virus, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests NPK reports support for other work from Sanofi Pasteur, Merck, Pfizer, Seqirus, and GSK, unpaid expert panel membership for a planned hepatitis E phase 2 vaccine clinical trial among pregnant women in Pakistan, and unpaid membership on the Western States COVID-19 Scientific Safety Review Workgroup, Board on Population Health and Public Health Practice, National Academies of Science, Engineering, and Medicine, and National Vaccine Advisory Committee Safety Subcommittee. SJG reports funding from the National Institutes of Health's National Center for Advancing Translation Sciences and National Institute of Mental Health. TCO reports consulting fees from Regenstrief Institute as a domain expert in patient matching in global health informatics, travel support from Regenstrief Institute and Patient-Centered Outcomes Research institute, and holds a patent (patent number PCT/US2018/047961). MBD, BED, and WFF report an additional CDC contract for the Vaccine Safety Datalink. TS reports unpaid participation as a member of the Advisory Committee on the Immunization Practices Influenza Vaccine Work Group, is chief of the Utah Adult Immunization Coalition, and is a member of the Utah Department of Health and Human Services Scientific Advisory Committee on Vaccines. OZ reports funding from the National Institute of Allergy and Infectious Diseases (grant number R01AI168373). NPK, JT, and KG report a CDC contract for VISION (contract number 75D30123C17595). SR reports funding from Biofire and GSK. MB reports speaker bureau participation for Innoviva Specialty Therapeutics. CEM reports funding from AstraZeneca, GSK, National Institutes of Health, US Department of Defense, and Patient-Centered Outcomes Research Institute, payment or honoraria for a lecture from Pri-Med, and leadership on the American Lung Association of Minnesota board, the Minnesota Department of Health Long COVID Advisory Committee, and on the Minnesota Department of Health Asthma Care Advisory Committee. JAW, PKM, SWB, SER, and EAKR report a CDC contract for VISION (contract number 75D30121D12779). KD, SAI, SJG, TCO, MBD, KN, BED, WFF, CR, KSA, and CEM report payments made to their institution by CDC via Westat. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>20</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39426837</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(24)01738-0</ArticleId><ArticleId IdType="pii">S0140-6736(24)01738-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>